Biocombinatorial Approaches for Drug Finding [electronic resource] / edited by W. Wohlleben, T. Spellig, B. Müller-Tiemann.

Call Number
611.01816
Title
Biocombinatorial Approaches for Drug Finding edited by W. Wohlleben, T. Spellig, B. Müller-Tiemann.
Physical Description
XVIII, 284 p. online resource.
Series
Ernst Schering Research Foundation Workshop, 0947-6075 ; 51
Contents
Protein Domain Fold Similarity and Natural Product Structure as Guiding Principles for Compound Library Design -- Sources of Polyketides and Non-Ribosomal Peptides -- Polyketide Synthases: Mechanisms and Models -- Functional and Structural Basis for Targeted Modification of Non-Ribosomal Peptlde Synthetases -- Prerequisites for Combinatorial Biosynthesis: Evolution of Hybrid NRPS/PKS Gene Clusters -- Engineering Glycosylation in Bioactive Compounds by Combinatorial Biosynthesis -- Glycosyltransferases and Other Tailoring Enzymes as Tools for the Generation of Novel Compounds -- Enzymatic Incorporation of Halogen Atoms into Natural Compounds -- From Glucose to Antibiotics: What Controls the Fluxes? -- Precursor-Directed Biosynthesis for the Generation of Novel Glycopetides -- Tool-Box: Tailoring Enzymes for Bio-Combinatorial Lead Development and as Markers for Genome-Based Natural Product Lead Discovery -- Natural Product Biosynthetic Assembly Lines: Prospects and Challenges for Reprogramming.
Summary
Genome- and proteome-based research is generating a significant increase in the number of available drug targets. Correspondingly there is an increasing need for novel, diverse compounds, particularly based on natural compounds, as screening resource. The purpose of the Ernst Schering Research Foundation Workshop 51 was to provide a forum for an open exchange on perspectives and limitations of biocombinatorial synthesis and the significance of this technology for future drug discovery in light of this challenge. Experts from academia and industry provided contributions covering: the significance of natural compounds for state-of-the-art drug discovery; the underlying basic principle for the biosynthesis of highly complex compounds; and the scope and limitations of combinatorial biosynthesis regarding formation, identification, optimisation, isolation and manufacturing of novel biologically active entities.
Added Author
Wohlleben, W. editor.
Spellig, T. editor.
Müller-Tiemann, B. editor.
SpringerLink (Online service)
Subject
MEDICINE.
MOLECULAR BIOLOGY.
PHARMACOLOGY.
Biomedicine.
Molecular Medicine.
Pharmacology/Toxicology.
Multimedia
  • Libraries with this item
Total Ratings: 0
No records found to display.
 
 
 
03683nam a22005295i 4500
001
 
 
vtls001568681
003
 
 
VRT
005
 
 
20170831184400.0
007
 
 
cr nn 008mamaa
008
 
 
170831s2005    gw |    s    |||| 0|eng d
020
$a 9783540270553 $9 978-3-540-27055-3
024
7
$a 10.1007/b138552 $2 doi
035
$a (DE-He213)978-3-540-27055-3
039
9
$y 201708311844 $z santha
050
4
$a QH506
072
7
$a MBGR $2 bicssc
072
7
$a PSD $2 bicssc
072
7
$a SCI049000 $2 bisacsh
072
7
$a MED067000 $2 bisacsh
082
0
4
$a 611.01816 $2 23
245
1
0
$a Biocombinatorial Approaches for Drug Finding $h [electronic resource] / $c edited by W. Wohlleben, T. Spellig, B. Müller-Tiemann.
264
1
$a Berlin, Heidelberg : $b Springer Berlin Heidelberg, $c 2005.
300
$a XVIII, 284 p. $b online resource.
336
$a text $b txt $2 rdacontent
337
$a computer $b c $2 rdamedia
338
$a online resource $b cr $2 rdacarrier
347
$a text file $b PDF $2 rda
490
1
$a Ernst Schering Research Foundation Workshop, $x 0947-6075 ; $v 51
505
0
$a Protein Domain Fold Similarity and Natural Product Structure as Guiding Principles for Compound Library Design -- Sources of Polyketides and Non-Ribosomal Peptides -- Polyketide Synthases: Mechanisms and Models -- Functional and Structural Basis for Targeted Modification of Non-Ribosomal Peptlde Synthetases -- Prerequisites for Combinatorial Biosynthesis: Evolution of Hybrid NRPS/PKS Gene Clusters -- Engineering Glycosylation in Bioactive Compounds by Combinatorial Biosynthesis -- Glycosyltransferases and Other Tailoring Enzymes as Tools for the Generation of Novel Compounds -- Enzymatic Incorporation of Halogen Atoms into Natural Compounds -- From Glucose to Antibiotics: What Controls the Fluxes? -- Precursor-Directed Biosynthesis for the Generation of Novel Glycopetides -- Tool-Box: Tailoring Enzymes for Bio-Combinatorial Lead Development and as Markers for Genome-Based Natural Product Lead Discovery -- Natural Product Biosynthetic Assembly Lines: Prospects and Challenges for Reprogramming.
520
$a Genome- and proteome-based research is generating a significant increase in the number of available drug targets. Correspondingly there is an increasing need for novel, diverse compounds, particularly based on natural compounds, as screening resource. The purpose of the Ernst Schering Research Foundation Workshop 51 was to provide a forum for an open exchange on perspectives and limitations of biocombinatorial synthesis and the significance of this technology for future drug discovery in light of this challenge. Experts from academia and industry provided contributions covering: the significance of natural compounds for state-of-the-art drug discovery; the underlying basic principle for the biosynthesis of highly complex compounds; and the scope and limitations of combinatorial biosynthesis regarding formation, identification, optimisation, isolation and manufacturing of novel biologically active entities.
650
0
$a MEDICINE.
650
0
$a MOLECULAR BIOLOGY.
650
0
$a PHARMACOLOGY.
650
1
4
$a Biomedicine.
650
2
4
$a Molecular Medicine.
650
2
4
$a Pharmacology/Toxicology.
700
1
$a Wohlleben, W. $e editor.
700
1
$a Spellig, T. $e editor.
700
1
$a Müller-Tiemann, B. $e editor.
710
2
$a SpringerLink (Online service)
773
0
$t Springer eBooks
776
0
8
$i Printed edition: $z 9783540220923
830
0
$a Ernst Schering Research Foundation Workshop, $x 0947-6075 ; $v 51
856
4
0
$u http://dx.doi.org/10.1007/b138552
912
$a ZDB-2-SBL
950
$a Biomedical and Life Sciences (Springer-11642)
999
$a VIRTUA               
No Reviews to Display
Summary
Genome- and proteome-based research is generating a significant increase in the number of available drug targets. Correspondingly there is an increasing need for novel, diverse compounds, particularly based on natural compounds, as screening resource. The purpose of the Ernst Schering Research Foundation Workshop 51 was to provide a forum for an open exchange on perspectives and limitations of biocombinatorial synthesis and the significance of this technology for future drug discovery in light of this challenge. Experts from academia and industry provided contributions covering: the significance of natural compounds for state-of-the-art drug discovery; the underlying basic principle for the biosynthesis of highly complex compounds; and the scope and limitations of combinatorial biosynthesis regarding formation, identification, optimisation, isolation and manufacturing of novel biologically active entities.
Contents
Protein Domain Fold Similarity and Natural Product Structure as Guiding Principles for Compound Library Design -- Sources of Polyketides and Non-Ribosomal Peptides -- Polyketide Synthases: Mechanisms and Models -- Functional and Structural Basis for Targeted Modification of Non-Ribosomal Peptlde Synthetases -- Prerequisites for Combinatorial Biosynthesis: Evolution of Hybrid NRPS/PKS Gene Clusters -- Engineering Glycosylation in Bioactive Compounds by Combinatorial Biosynthesis -- Glycosyltransferases and Other Tailoring Enzymes as Tools for the Generation of Novel Compounds -- Enzymatic Incorporation of Halogen Atoms into Natural Compounds -- From Glucose to Antibiotics: What Controls the Fluxes? -- Precursor-Directed Biosynthesis for the Generation of Novel Glycopetides -- Tool-Box: Tailoring Enzymes for Bio-Combinatorial Lead Development and as Markers for Genome-Based Natural Product Lead Discovery -- Natural Product Biosynthetic Assembly Lines: Prospects and Challenges for Reprogramming.
Subject
MEDICINE.
MOLECULAR BIOLOGY.
PHARMACOLOGY.
Biomedicine.
Molecular Medicine.
Pharmacology/Toxicology.
Multimedia